Attached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative Patents (Class 424/1.49)
  • Patent number: 10889651
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: January 12, 2021
    Assignee: Genentech, Inc.
    Inventors: Jyoti Asundi, Ron Firestein, Paul Polakis, Chie Sakanaka, Peter Chang, Rayna Takaki Venook
  • Patent number: 10874728
    Abstract: The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (TVM) in a subject comprising the step of administering a vaccine comprising a TVM or a nucleic acid encoding a TVM and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (TVM) or b) a nucleic acid molecule encoding said TVM.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: December 29, 2020
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: George Coukos, Andrea Facciabene
  • Patent number: 10849986
    Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: December 1, 2020
    Assignee: Immunomedics, Inc.
    Inventors: David M. Goldenberg, Serengulam V. Govindan
  • Patent number: 10780179
    Abstract: The present disclosure relates to conjugates, preferably, antibody-drug conjugates, directed against select non-transmembrane tumor antigens that are normally intracellular but can be secreted from cancer cells, such as human cathepsin D, and can be targeted in a way that enables the selective delivery of the conjugate to cancer cells. The design and mechanism of action disclosed enable the preferential delivery of the conjugate prodrug to cancer cells over normal cells for the purpose of selectively killing cancer cells. The uses of such conjugates for the treatment of cancer are described.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: September 22, 2020
    Assignee: IMMUNOBIOCHEM CORPORATION
    Inventor: Anton Neschadim
  • Patent number: 10765625
    Abstract: Provided are knottin-drug conjugates. The conjugates include a knottin peptide that includes an engineered loop that binds to a target on a cancer cell surface, and a drug (e.g., a nucleoside drug) conjugated to the knottin peptide through a linker. Also provided are pharmaceutical compositions and kits that include the knottin-drug conjugates, as well as methods of using the knottin-drug conjugates, e.g., for therapeutic purposes.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: September 8, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Nicholas Cox, Jennifer R. Cochran, Mark Smith, James R. Kintzing
  • Patent number: 10751284
    Abstract: Provided herein are tumor associated macrophage (TAM)-targeting liposome having a lipid bilayer; a targeting agent associated with the lipid bilayer, wherein the targeting agent comprises an antibody or fragment thereof that selectively binds a tumor associated macrophage; and a cytotoxic agent associated with the lipid bilayer, wherein the cytotoxic agent depletes tumor associated macrophages at or near the site of a tumor. Also provided are pharmaceutical compositions comprising the TAM-targeting liposomes and methods of treating a subject with cancer with the compositions.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: August 25, 2020
    Assignee: VERILY LIFE SCIENCES LLC
    Inventors: Stephen Morton, Graziella Solinas
  • Patent number: 10745346
    Abstract: Some novel compounds are provided in this disclosure. These novel compounds have potential SHP-1 agonist activity for being used in treating cancer.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: August 18, 2020
    Inventors: Kuen-Feng Chen, Chung-Wai Shiau
  • Patent number: 10739349
    Abstract: The present invention provides, among other aspects, stabilized chromophoric nanoparticles. In certain embodiments, the chromophoric nanoparticles provided herein are rationally functionalized with a pre-determined number of functional groups. In certain embodiments, the stable chromophoric nanoparticles provided herein are modified with a low density of functional groups. In yet other embodiments, the chromophoric nanoparticles provided herein are conjugated to one or more molecules. Also provided herein are methods for making rationally functionalized chromophoric nanoparticles.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: August 11, 2020
    Assignee: University of Washington through its Center for Commercialization
    Inventors: Daniel T. Chiu, Changfeng Wu, Xuanjun Zhang, Jiangbo Yu, Fangmao Ye
  • Patent number: 10736975
    Abstract: A patient specific therapeutic composition provided in a single dose container, the total volume of which may be administered to a patient in a single treatment session. The composition includes a monoclonal antibody having a labeled fraction and an unlabeled fraction, and a pharmaceutically acceptable carrier. The label may be any of a radioisotope or a drug such as a chemotherapeutic or cytotoxic agent. The amount of the monoclonal antibody and any conjugated label molecule may depend on at least one patient specific parameter selected from a patient weight, a patient age, a patient height, a patient gender, a patient medical condition, and a patient medical history. Methods of administration, production, and articles of manufacture comprising the patient specific therapeutic composition are also disclosed.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: August 11, 2020
    Assignee: Actinium Pharmaceuticals, Inc.
    Inventors: Kaushik J. Dave, Yulian Zhang
  • Patent number: 10651410
    Abstract: The present disclosure relates to an organic light emitting device including: a first electrode; a second electrode provided to face the first electrode; and an electron transport layer, an emitting layer and a hole transport layer provided between the first electrode and the second electrode, and the emitting layer contains doped protein quantum dots.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: May 12, 2020
    Assignee: Research & Business Foundation Sungkyunkwan University
    Inventors: June Kyun Park, Yong Han Roh, Sang Hyun Lee, Byung Chan Seo, Jae Won Jeong
  • Patent number: 10626176
    Abstract: Provided herein are embodiments relating to therapeutic applications of B7-H4 antibodies.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: April 21, 2020
    Assignee: JOUNCE THERAPEUTICS, INC.
    Inventors: Sriram Sathyanarayanan, Tatiana Novobrantseva, Virna Cortez-Retamozo
  • Patent number: 10604577
    Abstract: The invention provides methods and compositions for the prevention and treatment of advanced systemic mastocytosis such as systemic mastocytosis with an associated hematologic non-mast-cell lineage disease (SM-AHNMD). In particular, the invention provides methods for the prevention and treatment of advanced systemic mastocytosis through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of advanced systemic mastocytosis such as SM-AHNMD.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: March 31, 2020
    Assignee: Allakos Inc.
    Inventors: Christopher Robert Bebbington, Nenad Tomasevic, Rustom Falahati
  • Patent number: 10604558
    Abstract: The disclosure encompasses resurfaced cell-penetrating nanobodies and their methods of use. The resurfacing of nanobodies with positively-charged amino acids facilitates their penetration into a cell and allows targeting of a specific intracellular protein.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: March 31, 2020
    Assignee: Colorado State University Research Foundation
    Inventors: Brian R. McNaughton, Virginia J. Bruce
  • Patent number: 10590422
    Abstract: The present invention is directed to a method of treating cancer using interfering RNA duplexes to mediate gene silencing. The present invention is also directed to interfering RNA duplexes and vectors encoding such interfering RNA duplexes.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: March 17, 2020
    Assignee: PHYZAT BIOPHARMACEUTICALS, LDA.
    Inventor: Patricio Soares da Silva
  • Patent number: 10591492
    Abstract: Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: March 17, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Hartmuth Christian Kolb, Gallen Triana-Baltzer, John Randall Slemmon
  • Patent number: 10570195
    Abstract: An antibody or fragment thereof capable of binding to a neurotoxic tau protein. The neurotoxic tau protein includes a phosphorylation site at threonine residue 231 in AT180 domain of tau proteins and an amino acid substitution of proline residue 232 to glycine (P232G) in AT180 domain of tau proteins.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: February 25, 2020
    Inventor: Koorosh Shahpasand
  • Patent number: 10568951
    Abstract: The present invention relates to liquid pharmaceutical formulations for intravitreal injection of an anti-VEGF antibody which does not contain saccharides for use in the treatment of age-related macular degeneration.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: February 25, 2020
    Assignee: FORMYCON AG
    Inventor: Rainer Sigl
  • Patent number: 10562961
    Abstract: The invention provides IGFBP7 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: February 18, 2020
    Assignee: Astute Medical, Inc.
    Inventors: Ravi A. Vijayendran, Srivatsa Venkatasubbarao
  • Patent number: 10556024
    Abstract: The present invention, in some aspects, provides methods, reagents, compositions, and kits for the radiolabeling of proteins, for example, of proteins useful for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) (e.g., for diagnostic and therapeutic applications), using sortase-mediated transpeptidation reactions. Some aspects of this invention provide methods for the conjugation of an agent, for example, a radioactive agent or molecule to diagnostic or therapeutic peptides or proteins. Compositions comprising sortagged, radiolabeled proteins as well as reagents for generating radiolalebed proteins are also provided. Kits comprising reagents useful for the generation of radiolabeled proteins are provided, as are precursor proteins that comprise a sortase recognition motif.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: February 11, 2020
    Assignees: Whitehead Institute for Biomedical Research, The General Hospital Corporation
    Inventors: Mohammad Rashidian, Hidde L. Ploegh, Ralph Weissleder, Edmund J. Keliher
  • Patent number: 10538534
    Abstract: Analogs of largazole are described herein. Methods of treating cancer, blood disorders, autoimmune disease, and Alzheimer's Disease using largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 21, 2020
    Assignees: Colorado State University Research Foundation, Dana-Farber Cancer Institute, Inc., University of Notre Dame du Lac
    Inventors: Robert M. Williams, James E. Bradner, Dane Clausen, Olaf G. Wiest, Le Zhao, Christine Elizabeth Dunne
  • Patent number: 10456466
    Abstract: The present invention relates to antibodies which specifically bind vascular endothelial growth factor (VEGF), in particular heavy-chain antibodies, and more particularly single-domain antibodies. The present invention also relates to a method of producing the antibodies and the therapeutic uses thereof.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: October 29, 2019
    Assignee: Zhuhai Essex Bio-Pharmaceutical Co., Ltd.
    Inventors: Haizhou Fang, Wei Qu, Zanshun Zheng, Lanfang Zhuang, Xinzhi Wang
  • Patent number: 10406179
    Abstract: The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells with a combination of antibodies specific for CD117, and agents that modulate immunoregulatory signaling pathways, e.g. agonists of immune costimulatory molecules, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment, even in immunocompetent recipients.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: September 10, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Judith A. Shizuru, Irving L. Weissman, Kipp Andrew Weiskopf, Aaron Michael Ring, Akanksha Chhabra, Peter Schnorr
  • Patent number: 10383878
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: August 20, 2019
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, DAIICHI SANKYO EUROPE GMBH
    Inventors: Thore Hettmann, Reimar Abraham, Sabine Blum, Suguru Ueno
  • Patent number: 10358503
    Abstract: The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the {p}Ser404 Epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: July 23, 2019
    Assignee: New York University
    Inventor: Einar Sigurdsson
  • Patent number: 10352933
    Abstract: Detection and quantification of microbial colonization and biofilm formation on orthopedic explants would be important for deciding treatment interventions at the time of surgery. Methods and Systems for such treatments are shown that utilize various steps and kits to quickly generate confocal laser-scanning microscopy (CLSM) images to allow for the detection and quantification. The explants are prepared by applying antibodies of both gram-positive and grain-negative for at least one period of time.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: July 16, 2019
    Assignee: Rhode Island Hospital
    Inventors: Dioscaris Garcia, Christopher T. Born, John Jarrell
  • Patent number: 10344087
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: July 9, 2019
    Assignee: INNATE PHARMA
    Inventors: Cécile Bonnafous, Hélène Sicard, Renaud Buffet, Mathieu Blery
  • Patent number: 10335496
    Abstract: Provided herein are immunoconjugates comprising an anti-ROR1 antibody or an antigen-fragment fragment thereof and a drug moiety. These immunoconjugates are useful for treating ROR1 expressing cancers.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: July 2, 2019
    Assignee: VelosBio Inc.
    Inventors: Brian Lannutti, Katti Jessen, Thanh-Trang Vo, Jeffry Dean Watkins
  • Patent number: 10329350
    Abstract: The present invention relates to a method for producing multivalent Fab fragments. In particular, the invention relates to a method for the generation of trimeric Fab fragments by co-expression of a gene construct comprising a heavy chain portion of a Fab fragment and an in-frame fused collagen-like peptide, and a gene construct consisting of a light chain portion of an IgG in mammalian cells. Uses of molecules generated using the method of the invention are also described.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: June 25, 2019
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Min-Yuan Chou, Chuan-Chuan Huang, Hsiu-Chuan Li, Ya-Ping Lai
  • Patent number: 10323082
    Abstract: A method of treating tau pathologies, such as Alzheimer's disease, involving the administration of antibodies specific to the amino terminal region of human tau (amino acid residues 6-18 or 184-195) to provide passive immunization. The administration of such antibodies can reduce total tau levels, decrease tau hyperphosphorylation, and improve reference memory. Passive immunization with antibodies targeting the N-terminal projection domain of tau reduces both total and hyperphosphorylated tau was found effective in aged 3×Tg-AD mice, a generally accepted mouse model of Alzheimer's disease and frontotemporal dementia in humans.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: June 18, 2019
    Assignee: THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.
    Inventors: Khalid Iqbal, Inge Grundke-Iqbal
  • Patent number: 10322193
    Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: June 18, 2019
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
  • Patent number: 10280220
    Abstract: The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: May 7, 2019
    Assignee: IBC Pharmaceuticals, Inc.
    Inventor: Serengulam V. Govindan
  • Patent number: 10273310
    Abstract: Provided herein are methods for generating conjugated immunoglobulins, the method comprising: decapping a cysteine at amino acid position 80 (“Cys80”) in a light chain variable region of an immunoglobulin, wherein the immunoglobulin comprises a heavy chain variable region and the light chain variable region; and conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group. Antigen-binding molecules and methods for generating the same, immunoglobulins as well as nucleic acid molecules encoding the immunoglobulins and host cells comprising the nucleic acid molecules, conjugated immunoglobulins, and light chain variable regions for use in a conjugated immunoglobulin are also provided.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: April 30, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Luigi Grasso, Jared Spidel, James Bradford Kline, Earl Albone
  • Patent number: 10273297
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention provides the hybridomas that generate the monoclonal antibodies and the amino acid sequences of the variable regions of the monoclonal antibodies and chimeric antibodies comprising the amino acid sequences of the light and heavy chain variable regions.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: April 30, 2019
    Assignee: ZYMOGENETICS, INC.
    Inventors: Anthony W. Siadak, Shirley A. Rene, Janine M. Bilsborough
  • Patent number: 10265426
    Abstract: Disclosed herein is a method for preparing a scandium nano-radiopharmaceutical. The method comprises forming a plurality of scandium-encapsulated dendrimers by encapsulating scandium in polyamidoamine (PAMAM) dendrimers with amine surface groups, and forming a scandium nano-radiopharmaceutical by irradiating the plurality of scandium-encapsulated dendrimers by bombarding neutrons toward the scandium-encapsulated dendrimers.
    Type: Grant
    Filed: October 28, 2017
    Date of Patent: April 23, 2019
    Inventors: Navideh Aghaei Amirkhizi, Leila Moghaddam-Banaem, Mitra Athari Allaf, Sodeh Sajadi, Fariba Johari Daha
  • Patent number: 10265414
    Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: April 23, 2019
    Assignee: Immunomedics, Inc.
    Inventors: Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
  • Patent number: 10259868
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: April 16, 2019
    Assignee: ZYMOGENETICS, INC.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Patent number: 10246515
    Abstract: Provided herein are methods of using anti-LGR5 antibodies, for example, for treating a hedgehog-related disease including basal cell carcinoma.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 2, 2019
    Assignee: Genentech, Inc.
    Inventors: Frederic J. De Sauvage, Brian Biehs
  • Patent number: 10233252
    Abstract: A pH-dependent antibody that binds an antigen with high affinity at a first pH and rapidly dissociates at a second pH, wherein the antigen is a transferrin receptor (TfR), wherein the association at the second pH/the first pH is less than 20%, and wherein the pH-dependent antibody comprises at least two consecutive histidine residues at a single complementarity determining region (CDR) is disclosed.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 19, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Eric V. Shusta, Benjamin J. Tillotson
  • Patent number: 10232063
    Abstract: Accordingly, the present invention provides a method of treating lung neoplasia in a subject in need of treatment, by subjecting the patient to SIRT.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: March 19, 2019
    Assignee: Sirtex Medical Limited
    Inventors: Jens Ricke, Holger Amthauer, Oliver Grober
  • Patent number: 10226497
    Abstract: A method of treating neurological condition in a subject by administration of a pharmaceutical composition that excludes cardiac glycoside and excludes polysaccharide obtained from Nerium species or Thevetia species. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of the pharmaceutical composition to a subject.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: March 12, 2019
    Assignee: Phoenix Biotechnology, Inc.
    Inventors: Otis C. Addington, Robert A. Newman
  • Patent number: 10202449
    Abstract: Administration of an antibody that specifically binds IL-1? is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: February 12, 2019
    Assignee: XBIOTECH, INC.
    Inventor: John Simard
  • Patent number: 10202462
    Abstract: The present invention provides antigen-binding polypeptides (e.g., bi-specific antigen-binding polypeptides) that specifically bind to a first and a second target antigen with high affinity. The present invention also provides novel antigen-binding polypeptides that specifically bind to HER2 and antagonize HER2 activation. The invention also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen binding polypeptides. Methods of using antigen-binding polypeptide of the invention to treat disease (e.g., cancer) are also encompassed by the invention.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: February 12, 2019
    Assignee: X-BODY, Inc.
    Inventors: Yan Chen, Richard W. Wagner, Keming Zhang, Pascale Richalet
  • Patent number: 10202459
    Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 12, 2019
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, UNIVERSITY OF ULSAN, KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, PHAROSGEN
    Inventors: Youngro Byun, In San Kim, Ahmed Al-Hilal Taslim, Sang-Yoon Kim, Ye Ji Jang
  • Patent number: 10196439
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: February 5, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt Elvang, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • Patent number: 10188741
    Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: January 29, 2019
    Assignees: GAVISH-GALILEE BIO APPLICATIONS, LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
  • Patent number: 10183971
    Abstract: Isolated SAA peptides, fusion proteins and compositions comprising such are provided as are domain-specific SAA antibodies. Methods of treating sepsis and endotoxemia are also provided.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: January 22, 2019
    Assignee: The Feinstein Institute For Medical Research
    Inventors: Haichao Wang, Andrew E. Sama, Wei Li, Kevin J. Tracey
  • Patent number: 10159690
    Abstract: Provided is a chemically modified targeting protein, a pharmaceutical composition including the chemically modified targeting protein, a conjugate including the chemically modified targeting protein and a drug, and methods for preparing the same.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: December 25, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Su Young Chae, Sunghyun Kim, Sang Ok Song, Jae Il Lee
  • Patent number: 10155803
    Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: December 18, 2018
    Assignee: ZYMEWORKS INC.
    Inventors: Surjit Bhimarao Dixit, Igor Edmondo Paolo D'Angelo, David Kai Yuen Poon
  • Patent number: 10145849
    Abstract: [PROBLEM] To provide a monoclonal antibody against a biomarker which shows high specificity and can be effectively used in detection and diagnosis of various lesions relevant to various kinds of carcinomas and foci of necrosis, and so forth. [MEANS] A monoclonal antibody against a necrosis marker consisting the following amino acid sequence: (1) the amino acid sequence of SEQ ID NO: 1, or (2) an amino acid sequence having substitution, deletion and/or insertion of one or several amino acid residues in the amino acid sequence of (1) or sharing a homology of 90% or more with the amino acid sequence of (1), and showing the same function, activity or property as that of the amino acid sequence of (1) as a protein.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: December 4, 2018
    Assignee: FUJIFILM Corporation
    Inventors: Sumio Sugano, Yukari Kanzaki, Tsuneo Saga, Atsushi Tsuji
  • Patent number: 10138296
    Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: November 27, 2018
    Assignee: Cephalon, Inc.
    Inventors: Lynn Dorothy Poulton, Matthew Pollard, Anthony G. Doyle, Bridget Ann Cooksey, Vanya Pande, Adam William Clarke